期刊
EXPERIMENTAL AND THERAPEUTIC MEDICINE
卷 16, 期 2, 页码 1397-1402出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/etm.2018.6291
关键词
gestational diabetes mellitus; fibroblast growth factor-21; insulin resistance; glucose intolerance
资金
- Development of Science and Technology of the Department of Science and Technology of Guangzhou, China [201704020170]
Gestational diabetes mellitus (GDM) is a metabolic disease with symptoms of hyperglycemia, insulin resistance and fetal maldevelopment. Evidence has indicated that fibro-blast growth factor (FGF)-21 is a multifunctional protein and exhibits potential therapeutic value for metabolic diseases. The present study investigated the diagnostic value of FGF-21 serum levels in patients with GDM (n=50) and age-matched healthy individuals (n=50). It was demonstrated that the gene and protein expression levels of FGF-21 were downregulated in adipose cells in patients with GDM compared with those in healthy individuals. The results also indicated that the serum levels of FGF-21 were downregulated in patients with GDM compared with those in healthy individuals. In addition, it was demonstrated that blood glucose and blood pressure were higher in patients with GDM compared with those in healthy individuals. GDM patients had a markedly higher insulin resistance and glucose tolerance than healthy individuals. However, GDM patients had significantly lower serum levels of insulin than healthy individuals. It was observed that the serum levels of FGF-21 were positively correlated with those of glucose in GDM patients. In conclusion, these results indicate that decreased FGF-21 levels are associated with the risk of GDM, suggesting that FGF-21 may be a potential diagnostic factor for GDM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据